PMID- 31223310
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1687-8337 (Print)
IS  - 1687-8345 (Electronic)
IS  - 1687-8337 (Linking)
VI  - 2019
DP  - 2019
TI  - Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired 
      Primary/Recurrent Nonfunctioning Pituitary Adenomas.
PG  - 5731639
LID - 10.1155/2019/5731639 [doi]
LID - 5731639
AB  - This study investigated potential markers for predicting nonfunctioning pituitary 
      adenoma (NFPA) invasion and recurrence by high-throughput tissue microarray 
      analyses. We retrospectively studied two groups of patients: 60 nonrecurrent NFPA 
      cases that included noninvasion and invasion subtypes and 43 recurrent cases that 
      included primary NFPA. A total of 31 paired patient samples were evaluated (12 
      patients with one surgery and 31 who had undergone two operations, with both 
      tumors analyzed). Expressions of nuclear receptor subfamily 2 group C member 2 
      (NR2C2), B cell translocation gene 2, T-box-19 (TBX19), and cyclin-dependent 
      kinase 2 (CDK2) in surgically resected specimens were assessed by 
      immunohistochemistry. The relationships between marker expression and clinical 
      characteristics including age, sex, tumor volume, and follow-up time were 
      analyzed. Tumor volume and invasion as well as follow-up time were significantly 
      associated with invasion and recurrence (P < 0.01). Of the 60 nonrecurrent 
      samples, 15/41 and 13/19 showed high NR2C2 expression in the noninvasion and 
      invasion groups, respectively (chi (2) =5.287, P = 0.021). NR2C2 was also 
      overexpressed in 43 primary recurrent cases (chi (2) =5.433, P = 0.02), whereas 
      CDK2 (chi (2) = 11.242, P = 0.001) and TBX19 (chi (2) = 4.875, P = 0.027) were 
      downregulated. In the 31 paired samples, NR2C2 was more highly expressed in the 
      recurrent as compared to the primary tumor. High NR2C2 expression was associated 
      with NFPA invasion, recurrence, and progression, while TBX19 and CDK2 were 
      associated with NFPA recurrence.
FAU - Yao, Xiaohui
AU  - Yao X
AD  - Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China.
FAU - Zhang, Yazhuo
AU  - Zhang Y
AUID- ORCID: 0000-0002-8583-2580
AD  - Key Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical 
      Institute, Capital Medical University, Beijing, China.
FAU - Wu, Lijuan
AU  - Wu L
AD  - Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China.
FAU - Cheng, Rui
AU  - Cheng R
AD  - Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China.
FAU - Li, Chuzhong
AU  - Li C
AD  - Key Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical 
      Institute, Capital Medical University, Beijing, China.
FAU - Qu, Chongxiao
AU  - Qu C
AD  - Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China.
FAU - Ji, Hongming
AU  - Ji H
AUID- ORCID: 0000-0002-2127-1446
AD  - Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China.
LA  - eng
GR  - R01 AA020610/AA/NIAAA NIH HHS/United States
PT  - Journal Article
DEP - 20190516
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC6541973
EDAT- 2019/06/22 06:00
MHDA- 2019/06/22 06:01
PMCR- 2019/05/16
CRDT- 2019/06/22 06:00
PHST- 2018/10/06 00:00 [received]
PHST- 2019/03/12 00:00 [revised]
PHST- 2019/04/03 00:00 [accepted]
PHST- 2019/06/22 06:00 [entrez]
PHST- 2019/06/22 06:00 [pubmed]
PHST- 2019/06/22 06:01 [medline]
PHST- 2019/05/16 00:00 [pmc-release]
AID - 10.1155/2019/5731639 [doi]
PST - epublish
SO  - Int J Endocrinol. 2019 May 16;2019:5731639. doi: 10.1155/2019/5731639. 
      eCollection 2019.